

WHAT IS CLAIMED IS:

1. A method of preparing a pharmaceutical composition for treating or inhibiting obesity, comprising identifying a compound which inhibits de novo lipogenesis in a mammal, and incorporating said compound which inhibits de novo lipogenesis into a pharmaceutically administrable dosage form.
2. A method according to claim 1, wherein said compound is identified by measuring the effect of at least one candidate compound on carboanhydrase activity in a mammal, and selecting a compound which inhibits activity of at least one mammalian carboanhydrase.
3. A method according to claim 2, wherein said at least one carboanhydrase comprises a mammalian carboanhydrase of subtype II or subtype V.
4. A method according to claim 1, wherein said compound is substantially free of anticonvulsant properties.